Androgen Expression and Renal Cell Carcinoma Metastasis
According to the findings of a study published in Nature Communications, higher androgen receptor (AR) expression seems to increase clear cell renal cell carcinoma hematogenous metastasis but decreases lymphatic metastasis. The team of investigators were led by Chawnshang Chang, PhD, Director of the George H. Whipple Laboratory for Cancer Research at the University of Rochester Medical Center.
“This contrasting difference in the AR roles in [clear cell renal cell carcinoma] progression suggests that AR expression may play a distinct role in a stage-or tissue-specific manner,” reported Dr. Chang. “The detailed mechanisms, however, remain unclear.”
In addition, the researchers suggested that AR expression may play a key role in the differential metastatic destinations seen among men (more likely to proceed to hematogenous metastasis) and women (more likely to proceed to lymphatic) patients. Considering that available targeted therapies for metastatic clear cell renal cell carcinoma have a therapeutic durability of about 6 to 15 months, Dr. Chang and colleagues believe their study findings may help clinicians develop combined therapies using anti-AR and anti–vascular endothelial growth factor-C compounds to better suppress clear cell renal cell carcinoma progression.